120 related articles for article (PubMed ID: 38387232)
21. KDM1A Promotes Immunosuppression in Hepatocellular Carcinoma by Regulating PD-L1 through Demethylating MEF2D.
Wang Y; Cao K
J Immunol Res; 2021; 2021():9965099. PubMed ID: 34307695
[TBL] [Abstract][Full Text] [Related]
22. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions.
Wu K; Kryczek I; Chen L; Zou W; Welling TH
Cancer Res; 2009 Oct; 69(20):8067-75. PubMed ID: 19826049
[TBL] [Abstract][Full Text] [Related]
23. Hepatocellular carcinoma and CXCR3 chemokines: a narrative review.
Elia G; Fallahi P
Clin Ter; 2017; 168(1):e37-e41. PubMed ID: 28240761
[TBL] [Abstract][Full Text] [Related]
24. Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model.
Kong P; Yang H; Tong Q; Dong X; Yi MA; Yan D
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10685-10700. PubMed ID: 37306737
[TBL] [Abstract][Full Text] [Related]
25. IL-17 promotes hepatocellular carcinoma through inhibiting apoptosis induced by IFN-γ.
Li J; Zeng M; Yan K; Yang Y; Li H; Xu X
Biochem Biophys Res Commun; 2020 Feb; 522(2):525-531. PubMed ID: 31784083
[TBL] [Abstract][Full Text] [Related]
26. Role of MAPK activity in PD-L1 expression in hepatocellular carcinoma cells.
Xing S; Chen S; Yang X; Huang W
J BUON; 2020; 25(4):1875-1882. PubMed ID: 33099927
[TBL] [Abstract][Full Text] [Related]
27. LncTUG1 promotes hepatocellular carcinoma immune evasion via upregulating PD-L1 expression.
Wu R; Liu W; Yang Q; Zhang J; Hou P; Xiong J; Wu L; Li E
Sci Rep; 2023 Oct; 13(1):16998. PubMed ID: 37813900
[TBL] [Abstract][Full Text] [Related]
28. Sorafenib suppresses radioresistance and synergizes radiotherapy-mediated CD8
Cheng CC; Ho AS; Peng CL; Chang J; Sie ZL; Wang CL; Chen YL; Chen CY
Int Immunopharmacol; 2022 Nov; 112():109110. PubMed ID: 36037651
[TBL] [Abstract][Full Text] [Related]
29. Aucubin enhances the antitumor activity of cisplatin through the inhibition of PD-L1 expression in hepatocellular carcinoma.
Gao ZX; Zhang ZS; Qin J; Zhang MZ; Cao JL; Li YY; Wang MQ; Hou LL; Fang D; Xie SQ
Phytomedicine; 2023 Apr; 112():154715. PubMed ID: 36821999
[TBL] [Abstract][Full Text] [Related]
30. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.
Xiao G; Jin LL; Liu CQ; Wang YC; Meng YM; Zhou ZG; Chen J; Yu XJ; Zhang YJ; Xu J; Zheng L
J Immunother Cancer; 2019 Nov; 7(1):300. PubMed ID: 31727135
[TBL] [Abstract][Full Text] [Related]
31. Modified Biejia Jianwan decoction restrains PD-L1-mediated immune evasion through the HIF-1α/STAT3/NF-κB signaling pathway.
Tian X; Liu F; Wang Z; Zhang J; Liu Q; Zhang Y; Zhang D; Huang C; Zhao J; Jiang S
J Ethnopharmacol; 2024 Mar; 322():117577. PubMed ID: 38104877
[TBL] [Abstract][Full Text] [Related]
32. Hepatic IFIT3 predicts interferon-α therapeutic response in patients of hepatocellular carcinoma.
Yang Y; Zhou Y; Hou J; Bai C; Li Z; Fan J; Ng IOL; Zhou W; Sun H; Dong Q; Lee JMF; Lo CM; Man K; Yang Y; Li N; Ding G; Yu Y; Cao X
Hepatology; 2017 Jul; 66(1):152-166. PubMed ID: 28295457
[TBL] [Abstract][Full Text] [Related]
33. Aspirin enhances IFN-α-induced growth inhibition and apoptosis of hepatocellular carcinoma via JAK1/STAT1 pathway.
Li T; Dong ZR; Guo ZY; Wang CH; Tang ZY; Qu SF; Chen ZT; Li XW; Zhi XT
Cancer Gene Ther; 2013 Jun; 20(6):366-74. PubMed ID: 23703473
[TBL] [Abstract][Full Text] [Related]
34. RNA Methyltransferase FTSJ3 Regulates the Type I Interferon Pathway to Promote Hepatocellular Carcinoma Immune Evasion.
Zhuang Q; Dai Z; Xu X; Bai S; Zhang Y; Zheng Y; Xing X; Hu E; Wang Y; Guo W; Zhao B; Zeng Y; Liu X
Cancer Res; 2024 Feb; 84(3):405-418. PubMed ID: 37963197
[TBL] [Abstract][Full Text] [Related]
35. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model.
Kim KJ; Kim JH; Lee SJ; Lee EJ; Shin EC; Seong J
Oncotarget; 2017 Jun; 8(25):41242-41255. PubMed ID: 28465485
[TBL] [Abstract][Full Text] [Related]
36. Interferon-α and cyclooxygenase-2 inhibitor cooperatively mediates TRAIL-induced apoptosis in hepatocellular carcinoma.
Zuo C; Qiu X; Liu N; Yang D; Xia M; Liu J; Wang X; Zhu H; Xie H; Dan H; Li Q; Wu Q; Burns M; Liu C
Exp Cell Res; 2015 May; 333(2):316-326. PubMed ID: 25724899
[TBL] [Abstract][Full Text] [Related]
37. Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma.
Huang CY; Wang Y; Luo GY; Han F; Li YQ; Zhou ZG; Xu GL
J Immunother; 2017; 40(9):323-333. PubMed ID: 29028787
[TBL] [Abstract][Full Text] [Related]
38. Pathogenic Th17 cell-mediated liver fibrosis contributes to resistance to PD-L1 antibody immunotherapy in hepatocellular carcinoma.
Song M; Wang L; Jiang S; Liang J; Li W; Rao W; Du Q; Liu G; Meng H; Tang L; Li Z; Yang Y; Zhang L; Zhang B
Int Immunopharmacol; 2024 Mar; 129():111601. PubMed ID: 38350354
[TBL] [Abstract][Full Text] [Related]
39. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
[TBL] [Abstract][Full Text] [Related]
40. Interferon-γ induces immunosuppression in salivary adenoid cystic carcinoma by regulating programmed death ligand 1 secretion.
Fu Q; Liu X; Xia H; Li Y; Yu Z; Liu B; Xiong X; Chen G
Int J Oral Sci; 2022 Sep; 14(1):47. PubMed ID: 36167732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]